A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 134,700 shares of PSTX stock, worth $497,043. This represents 0.0% of its overall portfolio holdings.

Number of Shares
134,700
Previous 93,000 44.84%
Holding current value
$497,043
Previous $296,000 32.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.76 - $4.13 $177,810 - $266,071
64,424 New
64,424 $205,000
Q3 2023

Nov 14, 2023

SELL
$1.62 - $2.79 $141,456 - $243,620
-87,319 Reduced 99.15%
746 $1,000
Q2 2023

Aug 14, 2023

SELL
$1.66 - $3.4 $238,108 - $487,692
-143,439 Reduced 61.96%
88,065 $154,000
Q1 2023

May 15, 2023

BUY
$3.08 - $8.73 $584,556 - $1.66 Million
189,791 Added 454.99%
231,504 $713,000
Q4 2022

Feb 14, 2023

SELL
$3.33 - $6.38 $1.05 Million - $2.01 Million
-315,025 Reduced 88.31%
41,713 $221,000
Q3 2022

Nov 14, 2022

BUY
$2.43 - $4.51 $690,518 - $1.28 Million
284,164 Added 391.55%
356,738 $1.26 Million
Q2 2022

Aug 15, 2022

BUY
$1.87 - $5.0 $101,797 - $272,185
54,437 Added 300.14%
72,574 $187,000
Q1 2022

May 16, 2022

SELL
$3.22 - $7.04 $22,143 - $48,414
-6,877 Reduced 27.49%
18,137 $81,000
Q4 2021

Feb 14, 2022

BUY
$6.23 - $7.6 $26,813 - $32,710
4,304 Added 20.78%
25,014 $170,000
Q2 2021

Aug 16, 2021

SELL
$7.96 - $10.07 $918,170 - $1.16 Million
-115,348 Reduced 84.78%
20,710 $207,000
Q1 2021

May 17, 2021

BUY
$8.51 - $11.91 $1.16 Million - $1.62 Million
136,058 New
136,058 $1.3 Million
Q4 2020

Feb 16, 2021

SELL
$8.29 - $11.7 $369,029 - $520,825
-44,515 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$8.09 - $16.25 $360,126 - $723,368
44,515 New
44,515 $395,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $317M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.